Volixibat is an IBAT inhibitor, meaning that it blocks the function of the IBAT protein (ileal bile acid transporter), which is also called SLC10A2 (solute carrier family 10 member 2) or ASBT (apical sodium–bile acid transporter). IBAT is most highly expressed in the ileum, where it is found on the brush border membrane of enterocytes.

Volixibat is an oral, minimally absorbed agent designed to selectively inhibit the ileal bile acid transporter (IBAT). Volixibat may offer a novel approach in the treatment of adult cholestatic diseases by blocking the recycling of bile acids, through inhibition of IBAT, thereby reducing bile acids systemically and in the liver.

2012年2月1日 · Volixibat (SHP626 or LUM002, developed by Shire) is a highly selective, minimally absorbed ASBT inhibitor. It significantly increased the total amount of BAs in feces, attenuated hepatocyte hypertrophy, decreased hepatic TG and cholesteryl ester levels, and reduced mesenteric WAT deposition and NASH score in HFD-fed Ldlr -/- Leiden mice [182] .

Volixibat is an inhibitor of the apical sodium-dependent bile acid transporter (ASBT) that has been hypothesized to improve non-alcoholic steatohepatitis (NASH) by blocking bile acid reuptake and stimulating hepatic bile acid production. We studied the safety, tolerability and efficacy of volixibat in patients with NASH.

2024年6月17日 · An oral ileal bile acid transporter (IBAT) inhibitor, volixibat is a minimally absorbed agent potentially offering a novel approach in the treatment of adult cholestatic diseases by blocking the recycling of bile acids to reduce bile acids in the liver systematically.

2024年10月10日 · Volixibat, an oral IBAT inhibitor, offers a novel approach to treating adult cholestatic diseases by reducing systemic and liver bile acids. VANTAGE trial showed significant pruritus improvement and fatigue reduction with volixibat, with no new safety signals observed.

Volixibat is a selective inhibitor of the apical sodium-dependent bile acid transporter (ASBT), a transmembrane protein primarily expressed by enterocytes of the ileum. ASBT is primarily responsible for the recirculation of bile acids and therefore for …

What is Volixibat and how does it work? Volixibat is an investigational drug that works as an Ileal Bile Acid Transporter (IBAT) inhibitor. It is designed to reduce bile acid levels in the body, which may help alleviate symptoms associated with cholestatic conditions such as itching and potentially slow disease progression.

Volixibat is a selective inhibitor of the apical sodium-dependent bile acid transporter (ASBT), a transmembrane protein primarily expressed by enterocytes of the ileum. Also known as the ileal bile acid transporter (IBAT), ASBT is primarily responsible for the enterohepatic recirculation of bile acids and ultimately for hepatic lipid and ...

Volixibat (SHP626) is a highly selective, minimally absorbed, and competitive apical sodium-dependent bile acid transporter (ASBT) inhibitor. Volixibat has potential for treatment for non-alcoholic steatohepatitis (NASH).